The antiinflammatory properties of medroxyprogesterone acetate.
Rachoń
Dominik
D
D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000378:metabolism; D004336:Drug Antagonism; D004359:Drug Therapy, Combination; D019040:E-Selectin / Q000097:blood; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000517:prevention & control*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D017698:Postmenopause; D000685:Serum Amyloid A Protein / Q000378:metabolism; D013329:Structure-Activity Relationship
D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D015815:Cell Adhesion Molecules; D019040:E-Selectin; D004966:Estrogens, Conjugated (USP); D000685:Serum Amyloid A Protein; D002097:C-Reactive Protein; D017258:Medroxyprogesterone Acetate